Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FRNM
STRONG SELLFreenome, Inc. · Healthcare · United States · $1.2B · Avg Vol: $4M/d
11
StockRankGet insider-trade alerts
Q
15
V
24
M
48
P/E (TTM)
—
ROE
—
D/E
7.8x
Dividend %
—
COMPANY DESCRIPTION
Freenome is a healthcare diagnostics company developing early-detection tests for cancer through its proprietary multi-omics platform. Its moat is built on high-level R&D in blood-based screening, positioning the firm at the forefront of non-invasive diagnostics.
Loading 1Y...
PRICE (1Y)-0.2%
SMA 50SMA 200
Close
$11.38
RSI (14)
48.9
52W High
$14.47
From 52W High
0.8%
SCORE BREAKDOWN
Quality
15
ROIC
-46.4%16.6
ROE
—N/A
GP/Assets
-32.5%2.9
Op. Margin
-1474.3%6.0
FCF/Assets
-26.0%13.8
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
7.83x1.2
Current Ratio
1.89x35.4
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-9.1x25.0
P/FCF
—N/A
P/B
-0.2x25.0
P/S
34.8x12.4
Div Yield
—N/A
Momentum
48
52W High %
79%68.3
RS 6M
-27%36.2
SMA 50/200
0.96x56.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.2B
P/E (Forward)
—
Gross Margin
93.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FRNM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FRNM | Freenome, Inc.(you) | $1.2B | 11 | STRONG SELL |
| WGS | GeneDx Holdings Corp. | $1.8B | 14 | STRONG SELL |
| PSNL | Personalis, Inc. | $1.3B | 24 | SELL |
| CSTL | Castle Biosciences, Inc. | $749M | 19 | STRONG SELL |
| GRAL | GRAIL, Inc. | $2.9B | 19 | STRONG SELL |
| OPK | OPKO Health, Inc. | $921M | 35 | HOLD |
| FLGT | Fulgent Genetics, Inc. | $559M | 27 | SELL |
| MYGN | Myriad Genetics, Inc. | $530M | 35 | SELL |
| NEO | NeoGenomics, Inc. | $1.8B | 45 | HOLD |
| IMDX | Insight Molecular Diagnostics Inc. | $153M | 7 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%